Tag: Biotechnology Research

enGene
Global

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi’s promotion to Chief Medical Officer BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), today announced that Ron Cooper … Continue reading enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Impact Newswire
Orthobond
United States

Orthobond Expands its Board of Directors with Appointment of Eric Major as Chairman

Expansion of the Board and the company’s recent FDA Clearance marks the beginning of Orthobond’s commercialization phase PRINCETON, N.J. – Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, today publicly announced the appointment of Eric Major as the company’s Chairman of the Board. “We are pleased to be expanding Orthobond’s Board of Directors with the appointment … Continue reading Orthobond Expands its Board of Directors with Appointment of Eric Major as Chairman

Impact Newswire
CEL-SCI
United States

CEL-SCI Appoints Robert Watson as Chairperson of the Board

VIENNA, Va. – CEL-SCI Corporation (NYSE American: CVM) today announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to … Continue reading CEL-SCI Appoints Robert Watson as Chairperson of the Board

Impact Newswire
Ligand
United States

Ligand to Acquire APEIRON Biologics AG for $100 Million

Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the beginning of 2023 Transaction will be immediately accretive to Ligand EPS by an estimated $1.00 per share on an annualized basis with a $0.50 impact to … Continue reading Ligand to Acquire APEIRON Biologics AG for $100 Million

Impact Newswire
Agilent
United States

Agilent Names Bret DiMarco Chief Legal Officer

SANTA CLARA, Calif. – Agilent Technologies, Inc. (NYSE: A) today announced Bret DiMarco has been named to lead the company’s global legal organization as senior vice president and chief legal officer, as well as serving as secretary. He begins his new role with Agilent effective today. “Bret DiMarco is another outstanding addition to the Agilent leadership team,” said Padraig McDonnell, Agilent president and CEO. “Bret’s … Continue reading Agilent Names Bret DiMarco Chief Legal Officer

Impact Newswire
United States

Waypoint Bio Launches with $14.5M to Turbocharge Drug Discovery using in vivo Spatial Pooled Screening Technology

Company’s proprietary technology and lab-in-the-loop approach to be applied first to the discovery of novel, solid tumor cell therapies for cancers like pancreatic cancer NEW YORK – Waypoint Bio (aka “Waypoint”), a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology, today announced $14.5 million in seed funding led by Hummingbird Ventures with participation from other institutional investors, including Recode … Continue reading Waypoint Bio Launches with $14.5M to Turbocharge Drug Discovery using in vivo Spatial Pooled Screening Technology

Impact Newswire
X-Chem
United States

X-Chem Strengthens Its Data-Driven Discovery Services With New CBO Appointment

Industry Veteran Paul Davie Joins X-Chem Executive Team to Lead Strategic Growth and Partnerships WALTHAM, Mass. – Small molecule drug discovery acceleration experts and DNA-encoded library (DEL) technology pioneers X-Chem, Inc. welcomes Paul Davie as Chief Business Officer. He will lead global business development, focusing on the creation of new market opportunities for the company’s innovative technology platform and shaping new business ventures, collaborations and strategic partnerships to maximize the … Continue reading X-Chem Strengthens Its Data-Driven Discovery Services With New CBO Appointment

Impact Newswire
United States

bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain

For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. CAMBRIDGE, England – bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, today announces the launch … Continue reading bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain

Impact Newswire